| 0.163 0 (0%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.16 | 1-year : | 0.19 |
| Resists | First : | 0.13 | Second : | 0.17 |
| Pivot price | 0.11  |
|||
| Supports | First : | 0.09 | Second : | 0.07 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.12 |
| MA(100) : | 0.2 |
MA(250) : | 0.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.6 |
D(3) : | 25.9 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 3.88 | Low : | 0.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNBX ] has closed below the lower bollinger band by 3.0%. Bollinger Bands are 62.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.09 - 0.09 | 0.09 - 0.09 |
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Fri, 02 Oct 2026
BNB Plus shifts to institutional blockchain and AI infrastructure, evaluates monetization of LineaRx - TradingView
Fri, 24 Jul 2026
BNB Plus Corp. (BNBX) Q3 2025 Earnings: EPS Beats Estimates Despite Negative Earnings - Consensus Forecast Report - dars.gov.et
Wed, 15 Jul 2026
BNB Plus (OTCPK:BNBX) - Stock Analysis - Simply Wall Street
Tue, 14 Jul 2026
BNBX Stock Price and Chart — OTC:BNBX - TradingView
Mon, 13 Jul 2026
BNB Plus Received Notice of Delisting - TradingView
Mon, 13 Jul 2026
BNB Plus Receives Nasdaq Delisting Determination and Moves Trading to OTCQB Market - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 173 (K) |
| Shares Short P.Month | 140 (K) |
| EPS | 117.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.52 |
| Profit Margin | 0 % |
| Operating Margin | -535.4 % |
| Return on Assets (ttm) | -160.7 % |
| Return on Equity (ttm) | -439.5 % |
| Qtrly Rev. Growth | 98.9 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 0.38 |
| EBITDA (p.s.) | -5.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | 0 |
| PEG Ratio | 1.2 |
| Price to Book value | 0.05 |
| Price to Sales | 0.23 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|